Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benchmark analyst Bruce D. Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the pric...
-SEC Filing
Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate o...
FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ma...
